Answers drawn only from Teriparatide's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.
What is Teriparatide?
Teriparatide, also known as PTH(1-34), is a research compound in our hormonal reproductive category. Teriparatide is the first 34 amino acids of human parathyroid hormone and the first bone-anabolic drug approved for osteoporosis.
Is Teriparatide studied in women?
Teriparatide: of 4,368 PubMed records, 1,826 are tagged as including female subjects and 30 carry a sex-analysis tag. We grade this direct female evidence: at least one record carries a sex-analysis tag, so some findings are drawn from women rather than borrowed from mixed or male data. See how we read the evidence.
Has Teriparatide been studied during pregnancy or breastfeeding?
Contraindicated. Contraindicated in pregnancy and breastfeeding. There is no adequate human data and the label excludes use. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.
What evidence grade does Teriparatide have, and why?
Teriparatide carries evidence grade A. Approved indication with 1826 indexed studies that included female subjects.. Grades are derived from the research record, never hand-assigned; see how grades work.
Is there a female-specific dose for Teriparatide?
No. A female-specific dose for Teriparatide is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.
How is Teriparatide administered in research?
In the published literature, Teriparatide is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.
What side effects have been reported for Teriparatide?
Effects reported in the research literature include nausea, leg cramps, dizziness and orthostatic hypotension after early doses, transient hypercalcemia, injection-site reaction. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.
What is the CAS number for Teriparatide?
The CAS registry number for Teriparatide is 52232-67-4. It is also referred to as PTH(1-34), Forteo, recombinant human parathyroid hormone (1-34). Use it to confirm identity against a Certificate of Analysis.
How should Teriparatide be stored and handled?
Teriparatide sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.
Where can I buy Teriparatide for research?
Teriparatide is not currently listed by our research-use partner, Aurevena Research, but their catalog carries related compounds. Code research15 applies 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Browse the Aurevena catalog ↗